CoChat

Miscarriage in Women with Positive Anti-TPO Antibodies: Is Thyroxine the Answer?

Glinoer, Daniel · 2006 · The Journal of Clinical Endocrinology & Metabolism
Cited by 56

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The article by Negro et al. (1) in this issue of JCEM aimed at examining whether pregnant women who were euthyroid in the early stages of pregnancy but who have positive thyroid autoantibodies (TPO-Abs) would benefit from levothyroxine administration to improve the outcome of pregnancy and, more specifically, reduce the rate of spontaneous miscarriage and premature delivery. For this purpose, a large group of Caucasian pregnant women (n = 984) was investigated between November 2002 and October 2004. Measurements of TPO-Abs and thyroid function tests (TFTs) were carried out at the first prenatal visit. TFTs were repeated at 20 and 30 wk gestation and finally 3 d after delivery. Among the cohort, 115 women (11.7%) were shown to have positive thyroid autoantibodies (referred to hereafter as TAI positive). The first interesting observation of the study was that TAI-positive women were significantly older than the control population (mean age 30 vs. 28 yr; P < 0.05). The TAI-positive women were randomly assigned to two groups: group A (n = 57) received levothyroxine; group B (n = 58) received no treatment. TAI-negative women served as controls for TFTs and pregnancy outcome. Thus, the trial design in this study was randomized and prospective but not placebo controlled and hence not double blind (which is undoubtedly an inherent weakness). However, the medical participants to the study were kept unaware of the groups to which the patients belonged. Another possible criticism concerns the design of the intervention branch of the study. The rationale for deciding to administer 0.5 μg/kg·d of levothyroxine (when serum TSH was < 1 μU/ml), 0.75 μg/kg·d (when TSH was 1–2 μU/ml), and 1 μg/kg·d (when TSH was > 2 μU/ml or presence of a high TPO-Ab titer: > 1500 kIU/liter) was somewhat arbitrary although quite reasonable altogether. Median levothyroxine dosage in group A women was 50 μg/d. Once started, levothyroxine dosage was maintained unchanged throughout pregnancy. At the time of treatment onset (within 1 wk after the first gynecological visit), mean gestational ages were similar among the different groups (10.3–10.4 wk), although there was inevitably some variation in gestational ages within each group. One of the remarkable features of the present study was that levothyroxine administration was started quite early, between 5 and 10 wk gestation, in the majority of women in group A (37 of 57). A second interesting finding in the present study was that the mean serum TSH values, although normal, were already significantly higher at booking in TAI-positive women, compared with controls. A third interesting finding was that in group B women (TAI positive and no treatment), serum TSH levels increased progressively as gestation progressed, from a mean 1.7 μU/ml (12th wk) to 3.5 μU/ml (term), with 19% of untreated TAI-positive women having a supranormal serum TSH value at delivery. It should be noted that serum TSH levels also increased progressively in the control group but much less, from 1.1 μU/ml (12th wk) to 2.1 μU/ml (term), probably as the result of mild iodine deficiency in the population (2). Not only was the spontaneous serum TSH increment quantitatively significantly less marked in controls, compared with group B women, but also the control and group A (treated) women were able to maintain normal (unchanged) serum free T4 levels, whereas serum free T4 levels decreased by 30% during gestation in group B women, from 14.6 pmol/liter (10th wk) to 12.4 pmol/liter (30th wk; P < 0.05) and 10.2 pmol/liter (term; P < 0.05), as the consequence of a reduced functional thyroid reserve associated with chronic autoimmune thyroiditis (3). The fourth, and most novel and important, result of the study was that levothyroxine administration to TAI-positive women allowed for a significant decrease in the rate of obstetrical complications, with the miscarriage rate reduced by 75% (from 13.8 to ± 3.5%) and the frequency of premature delivery by 69% (from 22.4 to ± 7%). These results confirm entirely data produced previously by other authors showing an association between thyroid autoimmunity features and adverse obstetrical effects, even in the absence of thyroid dysfunction. They are important because, for the first time in a prospective, randomized study, they clearly show beneficial effects of levothyroxine administration on the outcome of pregnancy in women with thyroid autoimmunity and without an evident perturbation of thyroid function in early gestational stages (4, 5). An association between the risk of a miscarriage and autoimmune thyroid disease (AITD) was first reported 15 yr ago (6, 7). Since then, the statistical strength of this association has been largely confirmed in several population studies, leading authors to conclude that AITD without overt thyroid dysfunction was significantly associated with a 3- to 5-fold increase in overall miscarriage rate (8). In a recent review, a more detailed classification was attempte

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2006-0834

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 56

Metadata

Authors
Glinoer, D.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2006-07-01
Volume
91
Issue
7
Pages
2500-2502
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2145444701
Cited by
56
References
4
FWCI
3.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Miscarriage in Women with Positive Anti-TPO Antibodies: Is Thyroxine the Answer? https://app.cochat.ai/papers/10.1210/jc.2006-0834
The paper
Glinoer, D. (2006). Miscarriage in Women with Positive Anti-TPO Antibodies: Is Thyroxine the Answer? The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2006-0834

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.